In the mouse model, irisin mitigated TAC-induced cardiac hypertrophy and fibrosis, as indicated by reduced HW/BW, smaller cardiomyocytes, and improved echocardiography parameters (EF). Here, FNDC5 is linked to cardiac hypertrophy.